Details for Patent: 10,758,549
✉ Email this page to a colleague
Which drugs does patent 10,758,549 protect, and when does it expire?
Patent 10,758,549 protects OCALIVA and is included in one NDA.
This patent has thirty-four patent family members in twenty-five countries.
Summary for Patent: 10,758,549
| Title: | Compositions of obeticholic acid and methods of use |
| Abstract: | The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions. |
| Inventor(s): | Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon |
| Assignee: | Intercept Pharmaceuticals Inc |
| Application Number: | US16/787,796 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,758,549 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 10,758,549
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intercept | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-001 | May 27, 2016 | DISCN | Yes | No | 10,758,549 | ⤷ Start Trial | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA | ⤷ Start Trial | ||||
| Intercept | OCALIVA | obeticholic acid | TABLET;ORAL | 207999-002 | May 27, 2016 | DISCN | Yes | No | 10,758,549 | ⤷ Start Trial | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,758,549
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 104427 | ⤷ Start Trial | |||
| Australia | 2016255045 | ⤷ Start Trial | |||
| Australia | 2020205315 | ⤷ Start Trial | |||
| Brazil | 112017023161 | ⤷ Start Trial | |||
| Canada | 2983609 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
